Risk of major adverse cardiovascular events among second-line hormonal therapy for metastatic castration-resistant prostate cancer: A real-world evidence study.
Jui-Ming LiuCheng-Chia LinMiao-Fen ChenKuan-Lin LiuCheng-Feng LinTien-Hsing ChenChun-Te WuPublished in: The Prostate (2021)
The real-world evidence study revealed increased risks for MACE in mCRPC patients receiving second-line hormonal therapy.